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Chikungunya virus (CHIKV) has caused worldwide epidemics that impose a major burden
on health systems. Approximately half of infected individuals develop chronic debilitating
arthralgia, affecting their quality of life. Here, we identified the relevant clinical and demo-
graphic variables in the acute phase of CHIKV infection prospectively linked to chronic
arthralgia to elaborate a prognostic scoring system.
Methods
Acute CHIKV infection cases (n = 134) confirmed by serology or molecular test were exam-
ined <10 days of disease onset and followed for one year to evaluate for disease progres-
sion. Potential risk factors for chronic arthralgia were evaluated by multivariate analysis to
develop a prognostic scoring system, which was subsequently tested in an independent val-
idation cohort consisting of 42 individuals.
Results
A total of 107 out of 134 (80%) acute CHIKV-confirmed cases from the derivation cohort
were re-examined one year after enrollment. Chronic arthralgia post-CHIKV infection was
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diagnosed in 64 (60%). Five of the 12 parameters evaluated in the acute phase were statisti-
cally associated with persistent arthralgia and were further tested by Bayesian analysis.
These variables were weighted to yield a prognosis score denominated SHERA (Sex,
Hypertension, Edema, Retroocular pain, Age), which exhibited 81.3% accuracy in predicting
long-term arthralgia post-CHIKV infection in the derivation cohort, and 76.5% accuracy in
the validation cohort.
Conclusions
The simplified and externally validated prognostic scoring system, SHERA, is a useful
method to screen acutely CHIKV-infected patients at elevated risk of chronic arthralgia who
will benefit from specific interventions. This tool could guide public health policies, particu-
larly in resource-constrained settings.
Author summary
Debilitating articular pain frequently occurs as a consequence of Chikungunya virus infec-
tion, affecting individuals’ quality of life for a long time. Here we present a simple tool to
predict people at risk to remain with long-term articular pain after Chikungunya infec-
tion. We evaluated 134 patients acutely affected by Chikungunya virus searching for char-
acteristics previously described as related to persistent symptoms. We examined about
80% of those individuals after one year to identify those with persistent arthralgia. We
detected five features that represent good predictors and developed a scoring system
named SHERA (www.sheracalculator.com/shera), the acronyms of Sex (female), Hyper-
tension, Edema, Retroocular pain and Age (>26y). SHERA can correctly predict 8 out of
every 10 Chikungunya infected individuals that will persist with articular pain symptoms
at least one year after disease onset. These results were confirmed in the second group of
patients from another city affected by Chikungunya outbreak.
The easy-to-use scoring system can be applied in areas with limited access to health
support, helping to identify the ones who will need special care and benefit from early
intervention.
Introduction
Debilitating manifestations are attributed to infection by the arthritogenic chikungunya alpha-
virus (CHIKV). Until early 2000, sporadic outbreaks of chikungunya had been reported in
Africa and South Asia.[1] After 2004, the virus spread to Europe and the Americas, highlight-
ing potential for worldwide CHIKV dissemination.[2,3] In Brazil, several outbreaks have been
reported since the first case in 2014, with progressively higher numbers of affected individuals
with every successive epidemic.[4]
The acute phase of CHIKV infection, reported to be symptomatic in approximately 90% of
infected individuals, is characterized by rapid onset of fever, with intense and polyarticular
arthralgia, edema, cutaneous rash, pruritus, headache, nausea, retroocular pain and oral
lesions.[5] Notably, up to 87.2% of affected patients have persistently recurrent chronic skeletal
muscle symptoms and arthralgia lasting more than three months.[6–8] Chronic manifestations
post-CHIKV infection can lead to absenteeism with significant social and economic impacts.
[9,10]
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As no vaccine or effective treatment is available, chronic symptoms persisting after the
acute phase of CHIKV infection require special care.[11] Musculoskeletal deformities have
been described, in addition to aggravation of comorbidities, such as hypertension and diabe-
tes.[11–13] Renal failure and gastric complications related to the prolonged use of medications
to treat pain, as well as depression, have been reported.[11,14,15]
Early identification of individuals at risk for chronic manifestations subsequent to CHIKV
infection may optimize medical care. Prior work suggests that symptoms present during the
acute phase relate to chronicity and that persistent arthralgia occurs more frequently in
women, individuals over 40 years of age and those with preexisting comorbidities, such as
hypertension.[7,16–18] However, no attempt has been made to develop a clinical/sociodemo-
graphic scoring system to predict chronicity following acute CHIKV infection.
Herein, we performed periodic evaluations of clinical symptoms up to one year in two
cohorts of patients presenting clinically-, molecular- and/or serologically-confirmed CHIKV
mono-infection in the acute-phase. We then sought to determine predictors of long-term
arthralgia post-CHIKV infection to derive an easy-to-use prognostic scoring system.
Materials & methods
Ethics statement
This study was approved by the Institutional Review Board of the School of Medicine—Federal
University of Bahia—Brazil (derivation cohort—approval number: 1.657.324) and by the Institu-
tional Review Board of Bahia State University of Feira de Santana (validation cohort–- approval
number: 1.450.762).
Study population
A total of 230 individuals were recruited by active case detection in the derivation cohort
between 2016 and 2018 in the context of three concomitant outbreaks of arbovirus fever
(Zika/dengue/chikungunya). Two sites were selected in the state of Bahia (North: Campo For-
moso and South: Itabuna) and one in the state of Ceará (Maranguape) (S1 Fig). The two fur-
thest sites were over 1,000 km distant from each other (S1 Fig).
Our validation cohort was composed of 42 cases who met eligibility criteria from 219
CHIKV cases in Feira de Santana (Bahia State), site of the first outbreak of CHIKV in Brazil in
2014.[19] Patients were recruited at a health care unit and followed for twelve months.
Individuals were considered eligible if they reported feeling feverish, demonstrated fever or pre-
sented cutaneous rash in association with at least one of the following manifestations: cutaneous
pruritus, arthritis, arthralgia, headache, myalgia or retroocular pain (ROP). In both cohorts, individ-
uals were excluded if: 1. disease onset was longer than 10 days prior to time of recruitment; 2. no
sample was collected; 3.they tested negative for CHIKV by qRT-PCR and ELISA; 4. another con-
comitant arbovirus infection was detected by qRT-PCR or serology in blood, saliva or urine sample.
To identify possible early clinical markers of disease progression, all participants were ques-
tioned about the presence and duration of fever, maculopapular cutaneous rash (MPCR),
arthralgia, articular edema in the upper and lower extremities, ROP, myalgia, tendon pain and
other comorbidities. All patients underwent a clinical examination by one or two physicians to
assess acute signs of CHIKV infection such as rash and articular edema in addition to prior
comorbidities, such as hypertension, previous arthropathy and chronic peripheral edema. To
determine the evolution of arthralgia, these questions and clinical examination were repeated
at three and 12 months after onset of clinical symptoms in individuals with confirmed CHIKV
mono-infection. Individuals with confirmed CHIKV infection were classified as chronic
arthralgia post-CHIKV infection if they reported continuous or weekly episodes of new
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musculoskeletal pain or aggravation of prior arthritic pain (in the case of reported comorbid-
ity). All those with chronic arthralgia had one of the following, by history and physical exam:
persistent arthritis, tenosynovitis, and edema. Symptomatic treatment of acute and chronic
symptoms was performed, focused on pain relief as previously described.[11]
Quantitative Reverse Transcription PCR– qRT-PCR
EDTA-treated plasma, urine and oral swab samples were collected for molecular diagnosis of
ZIKV, DENV and CHIKV infection. RNA was extracted from plasma (140μL), urine (140μL)
and saliva (oral swab was incubated in 140μL of H2O nuclease free) samples using a commer-
cial Viral RNA isolation kit (QIAmp Viral RNA mini kit, Qiagen- Germany). Quantitative
RT-PCR was performed using two different assays: IBMP KIT BIOMOL ZDC (IBMP-Brazil)
or CDC Trioplex assay (CDC, USA) for ZIKV, CHIKV, DENV and RNAse P. All assays were
performed in accordance with manufacturer’s instructions.
Serological testing
Heparin-treated plasma samples were collected for serological diagnosis of ZIKV, DENV and
CHIKV infection. ELISA assays (Euroimmun, Germany) for detection of IgM antibodies
against ZIKV, DENV and CHIKV were performed according to manufacturer’s instructions.
A confirmed case was defined as a positive test for one of the laboratory criteria: a positive
qRT-PCR in serum, saliva or urine, or detection of specific IgM antibody.
Statistical analysis
Kolmogorov-Smirnov normality test determined the choice of parametric or non-parametric
testing using the Chi-squared test, Fisher’s exact test, One-way ANOVA, the Kruskal–Wallis
test. Receiver-operator (ROC) curve analysis was used to discretize continuous variables. To
evaluate evolution of arthralgia, Kaplan-Meier survival curves and log-rank testing were
employed. All statistical tests were two-tailed with a significance level of 5%.
All variables significant by univariate analysis were applied in compatible classifier algo-
rithms using the following linear and non-linear approaches: Neural Network, C5.0 algo-
rithms, Classification and Regression Tree (CART), Bayesian Network, Logistic Regression,
Quick Unbiased Efficient Statistical Tree (QUEST) and Chi-squared Automatic Interaction
Detection (CHAID). Each variable’s coefficient by multivariate analysis was used to build a
predictive clinical scoring model. The performance parameters were calculated using the
results predicted by clinical scoring system following formulas:
Sensitivity ¼ True PositiveðTPÞTPþFalse NegativeðFNÞ ; Specificity ¼
True NegativeðTNÞ
False PositiveðFPÞþTN ;
Positive Predictive Value : TPTPþFP ; Negative Predictive Value ¼
TN
TNþFN ; Accuracy ¼
TPþTN
TPþTNþFPþFN.
The confidence intervals for sensitivity, specificity, predictive values, and accuracy were calcu-
lated using the Clopper-Pearson method.
Data were analyzed using IBM SPSS version 25 (Armonk, NY: IBM Corp.), IBM SPSS
Modeler 18.2 (Armonk, NY: IBM Corp.) and GraphPad Prism 7.0 software (GraphPad Soft-
ware, USA).
Results
Description of derivation cohort
Among the 230 individuals initially screened, 96 patients were excluded for reasons listed in
Fig 1, yielding 134 exclusively infected with acute CHIKV (Fig 1). Of these, 60.1% of CHIKV
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cases tested positive by qRT-PCR, 57.1% by serology and 17.3% by both methods (Fig 2A). A
total of 16 cases were excluded due to ZIKV (n = 11) and DENV (n = 5) co-infection (Fig 2B).
Most prevalent symptoms included arthralgia in all patients, followed by fever, headache,
myalgia, edema, vomiting, ROP, MPCR, pruritus and hypertension. Of note, similar demo-
graphic data and clinical symptoms were observed at all recruitment sites (Table 1). A total of
107 patients were reevaluated after 12 months as 27 patients (20%) were unavailable for follow
up. Persistent arthralgia was detected in 64 (60%) individuals (Table 1).
Clinical symptoms associated with persistent arthralgia after 12 months of
follow-up
Of 12 demographic and clinical parameters investigated, edema (<0.0001), pruritus
(p = 0.0178), hypertension (p = 0.0065), ROP (p = 0.0036), sex (p = 0.0014) and age (dichoto-
mized at 26 years, p<0.0001) were statistically associated with persistent arthralgia at 12
months (Table 2). Age was dichotomized using area under curve (AUC) = 0.692 and Youden
Index = 0.392 (S2A and S2B Fig). Among these statistically significant observations, edema
demonstrated the highest odds ratio (OR = 13.46; CI = 4.827–32.91, p<0.0001), highlighting
its importance in development of chronic arthralgia after confirmed acute CHIKV infection
Fig 1. Flow chart of derivation cohort detailing exclusion criteria and number of cases excluded at each step.
Follow-up conducted at 12 months after onset of CHIKV symptoms.
https://doi.org/10.1371/journal.pntd.0008467.g001
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(Table 2). A heat map graph was generated to summarize the impact of age, hypertension and
other clinical signs and symptoms found to be significantly associated with chronic arthralgia
(Fig 3).
A Kaplan-Meier analysis of frequency of recovery reveals that from 42 patients that were
recovered at day 360, 21 (50%) were asymptomatic at day 14 (Fig 4).
Clinical predictors of persistent arthralgia after 12 months of follow-up
To better understand the independent values of each variable in classification of possible
cases of chronic arthralgia, multivariate analysis was performed in the derivation cohort,
Fig 2. (A)Diagnostic results of arbovirus infection (chikungunya, dengue and Zika virus) performed in the study
population (all 230 suspected cases). Molecular diagnosis was performed by qRT-PCR in EDTA-plasma, urine and
saliva samples and serological diagnosis was based of detection of IgM by ELISA in Heparin-plasma samples. Positive
CHIKV cases were represented in blue, DENV in red and ZIKV in green. Cases tested negative for all three arbovirus
were represented in brown. (B) Heat map showing diagnostic results of the patients excluded due to arbovirus co-
infection. Positive test (yellow), negative (blue) and not tested (white).
https://doi.org/10.1371/journal.pntd.0008467.g002
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considering all variables with p<0.05 (Fisher’s exact test) and multinomial logistic models
were built adding variables sequentially. The quality of each model was assessed by Akaike
information criterion (AIC). Accordingly, pruritus was excluded as addition of this variable in
the model worsened its performance.






Maranguape (n = 34) χ2 or Kruskal Wallis Total
(n = 134)
State Bahia Bahia Ceará
Year of recruitment 2016 2016 2017
Disease duration (days) 5 (2–7) 2 (1–3) 5 (2–8) 0.001 4 (2–6)
Patient characteristic
Age (years) 42.0 (28–54.0)� 33.0 (23.0–43.0)+ 43.5 (25.3–63.3) 0.419 39.0 (26.5–55)□
Sex (Female) 64.5% (49) 41.7% (10) 61.8% (21) 0.134 59.7% (80)
Fever 96.1% (73) 100% (24) 94.1% (32) 0.331 96.3% (129)
Myalgia 89.5% (68) 83.3% (20) 85.3% (29) 0.679 87.3% (117)
Arthralgia 100% (75) 100% (24) 100% (34) 1 100% (133)
Edema 69.7% (53) 54.2% (13) 76.5% (26) 0.188 68.7% (92)
MPCR 53.9% (41) 50% (12) 73.5% (25) 0.105 58.2% (78)
Pruritus 53.9% (41) 41.7% (10) 55.9% (19) 0.510 52.2% (70)
Headache 89.5% (68) 95.8% (23) 79.4% (27) 0.139 88.0% (118)
ROP 65.8% (50) 70.8% (17) 50.00% (17) 0.189 62.7% (84)
Vomits/Nausea 66.7% (50)� 62.5% (15) 76.5% (26) 0.469 68.4% (91)
Hypertension 21.1%(16) & 8.3%(2) 20.6%(7) 0.302 18.7% (25) □




& n = 74
MPCR = Maculopapular Cutaneous Rash
ROP = Retro-orbital pain
https://doi.org/10.1371/journal.pntd.0008467.t001
Table 2. Performance measures of significant variables in the derivation cohort.









































































1.68 2.700 (1.205 to
6.001)
0.0178
ROP = Retro-Orbital Pain
https://doi.org/10.1371/journal.pntd.0008467.t002
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The remaining variables were subsequently used in all compatible classifier algorithms. The
top three models based on AUC and accuracy were the Bayesian Network, Logistic Regression
and Classification and Regression Tree (CART). All three models showed similar results (S3
Fig 3. Heat map showing the presence (yellow) or absence (blue) of clinical and social demographic characteristics in individuals with chronic (n = 65) or recovered
(n = 42) arthralgia. Data were collected in the first 10 days of disease onset.
https://doi.org/10.1371/journal.pntd.0008467.g003
Fig 4. Recovery percentage of CHIKV-infected patients over the time. Recovery percentage was analyzed by Kaplan-Meier survival
curve (solid line) and 95% confidence intervals (dashed line). The numbers at risk represent the number of cases with arthralgia at each
time point.
https://doi.org/10.1371/journal.pntd.0008467.g004
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Fig). The Bayesian Network model presented the best overall accuracy (83.02%, AUC = 0.921;
S3 Fig).
The variable coefficients calculated by the Bayesian Network model were multiplied by 10
and used to build the predictive clinical scoring model. The nearest integer value was used to
assign a weight to each independent predictor. The resulting values were Edema = 2.5 points,
ROP = 2, Hypertension = 2, Age>26 = 1.5, Female = 1 (Fig 5A). This five-factor prognostic
clinical scoring scale, named SHERA score (Sex, Hypertension, Edema, Retroocular pain,
Age), presented an AUC of 0.909 (95%CI 0.852–0.966) and was split into two risk categories
(i.e., low and high risk of chronicity) according to the best accuracy indicated by Youden
Index. The best cutoff point was found to be� 5 points, indicating a high risk of chronicity,
while a score < 5 indicated low risk. We also built an online tool to calculate the SHERA score
value at www.sheracalculator.com/shera. The resulting performance measures in the deriva-
tion cohort were 81.31% (95%CI 72.62–88.19) accuracy, 84.62% (73.52–92.37) sensitivity,
76.19% (60.55–87.95) specificity, 84.62% positive predictive value and 76.19% negative predic-
tive value (Fig 5B).
Validation Cohort
The same diagnostic criteria used in the derivation cohort were applied to select 42 patients
included in the validation cohort. Baseline characteristics were similar to the derivation cohort,
as demonstrated in Table 3. Within the first 10 days of disease onset, fever, myalgia and head-
ache were more frequently reported, followed by MPCR, edema, pruritus, ROP, vomiting and
Fig 5. (A) SHERA Scoring System categories and score. (B) Performance measures of SHERA Scoring System (with the 95% confidence interval values in
parentheses) in derivation and validation cohorts.
https://doi.org/10.1371/journal.pntd.0008467.g005
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hypertension. Eight out of the 42 (19.05%) were lost to follow up, yielding 34 patients reevalu-
ated after 12 months. Persistent arthralgia was identified in 17 patients (50.00%) (Table 3 and
S4 Fig).
The application of the SHERA scoring model to predict persistence of arthralgia in the vali-
dation cohort resulted in an overall accuracy of 76.47% (58.83–89.25%) ([0.830 AUC (0.694–
0.966)], with 94.12(71.31–99.85)% sensitivity, 58.82(32.92–81.56)% specificity, 69.57% positive
predictive value and 90.91% negative predictive value (Fig 5B).
Discussion
The present study derived a simplified clinical scoring system shown to accurately predict chronic
arthralgia post-CHIKV infection in a Brazilian cohort of 107 individuals, and further validated
externally in an independent cohort of 42 patients. Only individuals with CHIKV mono-infection
were included in the study as other arbovirus infections were excluded by antibody and molecular
testing of serum, saliva and urine samples. Furthermore, only acute cases with initial evaluation
conducted within 10 days of disease onset were included to minimize recall bias.
The components of the SHERA scoring system have not been previously combined to com-
pose a prognosis system. It is important to note that all clinical and demographic markers
identified in the derivation cohort, used to compose the SHERA scoring system, had been pre-
viously linked to persistent symptoms as a consequence of CHIKV infection.[7,16,20–24] Age
was the most frequently mentioned predictor of persistent arthralgia, with a range of 20–60
years presenting increased risk of developing chronic arthralgia post-CHIKV infection.
[7,16,17,21,22] This reported variability in age range may be related to demographic differ-
ences among patients recruited, as well as study design. Increased risk in older populations has
been reported in studies based on telephone or e-mail interviews, excluding individuals youn-
ger than 18 years.[7,17] This strategy may have missed younger patients, thereby increasing





x2 or Kruskal Wallis
Year of recruitment 2016–2017 2015
Disease duration (days) 4 (2–6) 4 (2–6) 0.577
Patient characteristics
Age (years) 38.0 (26–55)� 39.0 (28.5–47) 0.778
Sex (Female) 59.7% (80) 61.9% (26) 0.799
Fever 96.3% (129) 92.9% (39) 0.355
Myalgia 87.3% (117) 92.9% (39) 0.319
Arthralgia 100% (134) 100% (42) 1
Edema 68.7% (92) 81.0% (34) 0.124
MPCR 58.2% (78) 81.0% (34) 0.0075
Pruritus 52.2% (70) 61.9% (26) 0.272
Headache 88.0% (118) 81.0% (34) 0.250
ROP 62.7% (84) 64.3% (27) 0.851
Vomits/Nausea 68.4% (91) 54.8% (23) 0.107
Hypertension 18.7% (25) � 16.7%(7) 0.770
Arthralgia persistence 60.7% (65/107)& 50.0%(17/34) + 0.272
�n = 132
MPCR = Maculopapular cutaneous rash
ROP = Retro-Orbital Pain
https://doi.org/10.1371/journal.pntd.0008467.t003
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the median age of the observed population. In our cohorts, active recruitment and clinical
evaluation by a physician at all time-points ensured accurate representation of all age groups.
Almost 25% of the patients recruited herein were under 26 years of age, and only 25% pre-
sented with symptoms one year after disease onset, compared to 73.42% of individuals older
than 26 years. Similarly, a prior study demonstrated chronicity in 17% of individuals
aged< 25 years and increased risk of chronicity in those over 25 years of age.[24]
A higher proportion of women (72,31%) was found in the group with chronic arthralgia
post-CHIKV infection compared to those who recovered after acute disease (47,62%). Concor-
dantly, previous studies have reported an increased risk of long-term arthralgia in women.
[20,22,25]
Edema, hypertension and ROP were also related to the persistence of chronic arthralgia
post-CHIKV infection. Development of edema at early stages of infection may be a hallmark
of an intense anti-CHIKV immune response or proliferative viral activity in the joints that ulti-
mately results in chronic tissue damage and arthritis.[26] However, prior arthropathy or
peripheral vascular disease should be investigated to exclude any other possible causes of
edema, especially in the lower extremities. Furthermore, hypertensive individuals were also
more likely to persist with arthralgia, as previously reported.7 This condition also seems to be
associated with more severe outcomes and increased mortality in the acute phase of CHIKV
infection.[27,28] Together, these data suggest the possible synergistic action of an arthritogenic
virus with other inflammatory conditions that compound clinical manifestations. While we
speculate that both edema and ROP in individuals who develop persistent arthralgia post-
CHIKV infection may be indicative of exacerbated systemic inflammation during the acute
phase, comprehensive investigation of such a mechanism has yet to be performed.
Among the group of patients who recovered and did not develop chronic arthralgia post-
CHIKV infection, approximately 60% reported being asymptomatic within a month of initial
symptoms. This may be linked to rapid viral clearance due to effective early mechanisms of
immune defense that seem to influence clinical recovery.[29]
While our study has multiple strengths, a potential limitation may be that both derivation
and validation cohorts are from the same region and with relatively small sample size. While
they were recruited during outbreaks from different years, with a rigorous inclusion criteria, it
is possible that there is genetic variability of patients and differences in CHIKV genotypes that
could affect the accuracy of the proposed score. Although the variables used as part of the par-
simonious score have been individually published worldwide previously, the robustness of the
SHERA score in patients requires additional evaluation with a larger sample size in distinct
geographic areas at risk for CHIKV infection. Additionally, specificity seemed to be the weak-
est parameter of SHERA Scoring System specially in the validation cohort, suggesting this
prognosis tool may be used primarily for screening and it may be improved by adding novel
biomarkers.
While no specific treatment is available for CHIKV, the identification of a precise tool that
predicts those at risk for chronicity could significantly impact patient care. Individuals at risk
for chronicity would benefit from a multidisciplinary therapeutic approach and careful moni-
toring of comorbidities potentially aggravated by CHIKV infection. Given that CHIKV has an
elevated attack rate and high predilection for chronicity, the SHERA score could aid in predict-
ing the frequency and distribution of chronic cases, effectively targeting public health services
in at risk areas and mitigating the socioeconomic impact of arthralgia post-CHIKV infection.
This study highlights the reliability of a novel validated easy-to-use clinical score for risk of
chronicity in CHIKV infection. As a simple and inexpensive tool that uses clinical informa-
tion, this prognostic scoring system may be effective in limited resource settings and aid in
guiding public health policies to alleviate the social economic impacts of CHIKV infection.
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S2 Fig. A) Performance of age to predict arthralgia after one year using Area Under the Curve
analysis. B) Relative values of chronic arthralgia with respect to age groups.
(TIF)
S3 Fig. Performance of multivariate models designed to predict chronic arthralgia post-chi-
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(TIF)
S4 Fig. Flow chart of validation cohort showing exclusion criteria and number of cases
excluded at each step. Follow-up conducted 12 months after onset of CHIKV symptoms.
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